EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Differential impact of host-related factors on survival outcomes between IO+IO and IO+TKI in metastatic renal cell carcinoma: a multicenter retrospective study

Koichi Sugimoto, Shingo Toyoda, Lan Inoki, Keiichiro Mori, Takafumi Yanagisawa, Keita Tamura, Takuhisa Nukaya, Ryoichi Maenosono, Hirofumi Morinaka, Shingo Nishimura, Kensuke Bekku, Kazumasa Komura, Kiyoshi Takahara, Teruo Inamoto, Haruhito Azuma, Kazutoshi Fujita

International Journal of Clinical Oncology · 2026-08 · 31 (8) · 1658-1667

DOI: 10.1007/s10147-026-03075-2 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Immune checkpoint inhibitor (ICI)-based combination therapies, including immune checkpoint inhibitor plus immune checkpoint inhibitor (IO + IO) and immune checkpoint inhibitor plus tyrosine kinase inhibitor (IO + TKI) regimens, have significantly improved outcomes in metastatic renal cell carcinoma (mRCC). However, the prognostic impact of host-related factors in patients receiving these therapies remains unclear. Methods We retrospectively analyzed 493 patients with mRCC treated with IO+IO ( n = 205) or IO+TKI ( n = 288) as first-line therapy. Survival outcomes and treatment responses were evaluated according to host-related factors using Cox proportional hazards models. Results In the IO+IO cohort, multiple host-related factors were independently associated with worse overall survival, including BMI < 25 kg/m 2 (HR 2.280, p = 0.007), dyslipidemia (HR 2.079, p = 0.019), PPI use (HR 1.605, p = 0.039), and opioid use (HR 2.919, p = 0.008). In contrast, in the IO+TKI cohort, only IMDC poor risk (HR 4.169, p < 0.001) and opioid use (HR 3.328, p < 0.001) were significantly associated with overall survival. Host-related factors showed limited associations with objective response and disease control rates in both cohorts. Conclusion The prognostic impact of host-related factors differs according to treatment regimen in mRCC. These findings suggest that host immune and metabolic conditions play a more prominent role in immune-driven IO+IO therapy, whereas tumor-related factors may predominate in IO+TKI therapy.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →